High-throughput, automated analysis of viral vector titer and process-related impurities accelerates downstream process development of AAV-based gene therapies
Cell & Gene Therapy Insights 2022; 8(9), 1079;
DOI: 10.18609/cgti.2022.159
Published: 30 September 2022
FastFacts
Watch the video or read the poster to learn:
- How to use a single, automated platform for both viral vector titer and impurity analysis
- Why fully automated, microfluidic immunoassays provide a time- and sample-saving alternative to ELISA techniques
- How to deploy a strategy for shortening analysis time, reducing sample volume, and dramatically increasing walkaway time